Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Grade 2 GEP-NETs have inherent tumor heterogeneity seen with positive expression of somatostatin (SSTR) and glucose (GLUT) receptors. Prior surgical resection and imaging parameters on Ga-68 DOTANOC PET/C are well-established variable impacting prognosis in well-differentiated grade 1 NETs. Since the degree of differentiation is variable in Grade 2 NETs, these parameters have not been studied.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Puranik A
Authors: Puranik A, Agrawal A, Rangarajan V, Shrikhande S, Dev I,
Keywords: Grade 2, GEP-NET, DOTANOC, surgical resection,
Introduction: PET/CT imaging of patients with neuroendocrine neoplasms (NEN) 1 hour (h) post injection (pi) of 64Cu-DOTATATE has shown superiority in lesion detection when compared to other clinically available somatostatin receptor imaging (SRI) modalities.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Loft M, Johannesen H, Carlsen E, Johnbeck C, Binderup T,
Keywords: 64Cu-DOTATATE, Neuroendocrine Neoplasms, PET Imaging, Somatostatin Receptor Imaging,
Introduction: Peptide radioreceptor therapy (PRRT) is a promising therapy option for SSTR2-positive pancreatic neuroendocrine neoplasms (NEN). However, therapeutic effects are often not satisfying concerning sensitivity to PRRT. We hypothesize that the slow proliferation of NENs provides sufficient time for the repair of beta-particle induced-DNA damage. The ubiquitin-proteasome-system is involved in DNA damage repair and affected by the proteasome inhibitor bortezomib (Velcade®). The inhibition of DNA damage repair during PRRT may be an option to improve therapy response in NEN. We have recently demonstrated the damage repair inhibitory and pro-apoptotic effect of bortezomib in NEN in vitro (Briest et al., in revision).
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Briest F
Authors: Briest F, Grötzinger C, Exner S, Sedding D, Baum R,
Keywords: peptide radioreceptor therapy, Lu-177-DOTATOC, PRRT, bortezomib, in vivo model, SPECT/CT Imaging, chicken CAM model, Sensitizer, DNA damage repair,
Introduction: High-grade neuroendocrine carcinomas (NECs) possess inevitable tendencies to metastasise and hold poor prospects of survival. Patients with neuroendocrine tumours who progress after medical management can be treated with peptide receptor radionuclide therapy (PRRT), on the proviso that there is positive uptake on 68Ga-DOTATATE PET/CT imaging. Despite this, a proportion of patients who exhibit positive imaging respond poorly to therapy. Management of NECs is currently limited; evidence for treating NECs with PRRT is scarce.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Butt S, Evans J, Sharma R,
Keywords: neuroendocrine, carcinoma, tumours, PRRT,
Introduction: The majority of patients diagnosed with gastroenteropancreatic (GEP)-NETs present metastases expressing somatostatin receptor 2 (SSTR2). The 68Gallium-labelled SSTR2 antagonist 68Ga-OPS202 has shown improved diagnostic performance as a PET imaging agent compared with the SSTR2 agonist 68Ga-DOTA-TOC in a single-centre study.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Virgolini I, Brouwers A, Haug A, Grønbæk H, Kjær A,
Keywords: 68Ga-OPS202, GEP-NET, SSTR2, optimal dose range,